Appili Therapeutics Inc Class A (TSE:APLI) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Appili Therapeutics Inc., a biopharmaceutical company specializing in infectious diseases, has reported unanimous shareholder approval for all resolutions at its annual and special meeting. Key outcomes include the re-election of directors, the re-appointment of PricewaterhouseCoopers as independent auditor, and approval for the company’s transition under the Business Corporations Act (Ontario). These decisions mark a strong mandate for the company’s direction and governance.
For further insights into TSE:APLI stock, check out TipRanks’ Stock Analysis page.